Sachetta’s Ligand Pharmaceuticals LGND Stock Holding History

Sachetta’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-21	Closed	-$2.36K	–	1267
2024 Q2	$2.36K	Sell	21 -2	-9%	-$159	﹤0.01%	783
2024 Q1	$1.64K	Hold	23	–	–	﹤0.01%	777
2023 Q4	$1.64K	Buy	+23	New	+$1.36K	﹤0.01%	777

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Sachetta's LGND Position: Q3 2024 in Review

Sachetta sold out of Ligand Pharmaceuticals (LGND) in Q3 2024, closing a stake of 21 shares — an estimated $2.36K sold.

Sachetta first reported a position in LGND in Q4 2023 and held it in 3 quarters. The position peaked at $2.36K in Q2 2024. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

Sachetta reported no remaining Ligand Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Sachetta sold 21 Ligand Pharmaceuticals shares in Q3 2024, an estimated $2.36K.
Sachetta first reported a position in Ligand Pharmaceuticals in Q4 2023 and held it in 3 quarters.
Sachetta's Ligand Pharmaceuticals position peaked at $2.36K in Q2 2024.
243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on Sachetta's 13F filing for Q3 2024, filed 8 Nov 2024.